Late Infections Seen With Rituxan in VasculitisMedPage TodayLIVERPOOL — Treatment of vasculitis associated with antineutrophil cytoplasmic antibodies (ANCA) with rituximab (Rituxan) is known to be effective, but in a U.K. cohort was associated with an…
MedscapeAntineutrophil Cytoplasm Antibody-Associated VasculitisMedscapeRituximab, an anti-CD20 monoclonal antibody, has proven efficacy in remission induction therapy for AAV, and two trials with rituximab as remission maintenance therapy are ongoing. …
MedscapeNot Clear: Best Use of Rituximab in Follicular LymphomaMedscapeThe opinion piece, from Stephen Ansell, MD, from the Mayo Clinic in Rochester, Minnesota, accompanies the published final results of a phase 3 trial that compared 2 different regime…
|
Brampton woman denied OHIP coverage for life-saving cancer drugs
Caledon Enterprise The other drug, Rituximab, is approved for second line use, but only in tandem with Fludarabine — a drug that Mitchell can’t take because she suffered an extreme, adverse reaction to it during her first bout with chemotherapy. “The drugs that my … |
|
Brampton woman denied OHIP coverage for life-saving cancer drugs
Mississauga The other drug, Rituximab, is approved for second line use, but only in tandem with Fludarabine — a drug that Mitchell can’t take because she suffered an extreme, adverse reaction to it during her first bout with chemotherapy. “The drugs that my … |
Minimal residual disease associated with overall survival in leukemiaThe Oncology ReportDr. Paolo Strati and his associates studied 237 chronic lymphocytic leukemia (CLL) patients who were undergoing first-line treatment with fludarabine, cyclophospham…
Maintenance rituximab extended PFS, not OS in follicular lymphomaHealioPatients with follicular lymphoma who achieved stable disease with rituximab-based induction therapy demonstrated extended PFS and time to next treatment when they received maintena…
Bristol Post92 Club: Bristol football fans to visit all 92 grounds for Invest In ME charityBristol PostMoney raised will go towards UK trials of the drug Rituximab. A 2,600-mile route is due to be completed in 92 hours of driving, spread out over the c…
|
VIDEO: IACFS/ME Conference – Summary of Research by Dr. Komaroff
ProHealth In terms of the cytokine changes that we’re seeing consistently over various labs all over the world as well as NK cell function, how can we use biologics in terms of the Norwegian study with Rituximab to make sense of any improvement in certain patients? |
The Pharma Letter |
Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy …
The Pharma Letter It is expected that these agents will be added to rituximab-containing regimens, such as bendamustine (Teva Pharmaceutical Industries’ Treanda, Mundipharma’s Ribomustin/Levact, Symbio Pharmaceuticals/Eisai’s Treakisym) in combination with rituximab, … |